BioCentury | Jan 26, 2018
Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

...ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of...
...18-month OS rate of 18.6%. The historical study enrolled 342 patients with metastatic cancer only. CCX872...
...receptor 2 (CCR2; CD192) antagonist. Last year, ChemoCentryx reported data from the trial showing that CCX872...
BioCentury | Jan 23, 2018
Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

...ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of...
...18-month OS rate of 18.6%. The historical study enrolled 342 patients with metastatic cancer only. CCX872...
...receptor 2 (CCR2; CD192) antagonist. Last year, ChemoCentryx reported data from the trial showing that CCX872...
BioCentury | Dec 19, 2017
Distillery Therapeutics

Cancer

...nephropathy and in preclinical testing to treat focal segmental glomerulosclerosis (FSGS). ChemoCentryx Inc. also has CCX872...
BioCentury | Sep 12, 2016
Clinical News

CCX872: Phase Ib data

...in an open-label, U.S. and Dutch Phase Ib trial showed that twice-daily 150 mg oral CCX872...
...37% and a disease control rate (DCR) of 78%. In the intent-to-treat (ITT) population (n=50), CCX872...
...to an ORR of 30% and a DCR of 64%. All responses were partial responses. CCX872...
BioCentury | May 4, 2015
Clinical News

CCX872: Phase Ib started

...ChemoCentryx began an open-label Phase Ib trial to evaluate 150 mg oral CCX872 twice daily plus...
...for >=12 weeks in up to 54 patients. ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX872...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: CC chemokine receptor 2 (CCR2; CD192)

...associated with inflammatory gene expression. In the mouse model, subcutaneous injection of the CCR2 antagonist CCX872...
...steps could include testing CCR2 antagonists in additional models of brain injury. ChemoCentryx Inc. has CCX872...
BioCentury | Dec 10, 2012
Clinical News

CCX872: Phase I started

...ascending-doses of oral CCX872 in 40 healthy volunteers. ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX872...
BioCentury | Oct 29, 2012
Clinical News

ChemoCentryx preclinical data

...In a genetic mouse model of diabetic nephropathy, CCX872 produced a "pronounced improvement" in albuminuria and...
...for the Study of Diabetes meeting in Berlin. ChemoCentryx could not be reached for details. CCX872...
...receptor 2 ( CCR2 ; CD192 ) inhibitor. ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif. Product: CCX872...
Items per page:
1 - 8 of 8